Life Sciences Archive » July, 2022

Life Sciences - July, 2022

298 articles

• The 2022 Regional Powerhouses
• Biden's 1st Circ. Pick, Abortion Rights Atty, Up Against Clock
• 10th Circ. Tosses Sanofi's EpiPen Antitrust Suit Against Mylan
• SEC Says Pharma Adviser Passed Insider Tips To His Family
• Fed. Circ. Won't Nix Revival Of UMass IP Suit Against L'Oreal
• Cannabis Bill Roundup: Congress Kicks Off Reform Agenda
• DQ'd Tenn. Judge Suspended For Media Interviews, Affair
• Post-Dobbs HHS Guidance Brings Privacy Considerations
• Sepsis Testing Trial Ends In $2.1M Patent Verdict In Del.
• USPTO Clarifies IP Disclosure Duties Amid Drug Pricing Push
• Hatch-Waxman Allowed Prevacid IP Suit, Takeda Tells 3rd Circ.
• In-House At A Cannabis Company
• In-House At A Cannabis Company: The Int'l Trademark Issues
• 2nd Circ. Backs NY Schools' 2019 Update To Vaccine Rules
• Cross-Border M&A Atty Joins Norton Rose's NY Practice
• S. Africa Targets EU Citrus Regs With First-Ever WTO Case
• Allergan Reaches Deal To Pay $2.37B To Settle Opioid Suits
• CR Bard's Mesh Design Was Substandard, Patient Says
• Biogen Denies Misleading Investors Over Alzheimer's Drug
• Fed. Circ. Forecast: Nike Returns To Defend A Patent
• JPML Mulls Individualized Causation In Gardasil Vax Suits
• Abbott Labs' Judge Choice Leads To JPML Conflict Questions
• 2 NJ Firefighters Admit Roles In $50M Drug Fraud Scheme
• HHS Fraud Alert Is A Major Warning To Telehealth Industry
• Albright's Dimmed Power Upsets New Waco Patent Practices
• Ex-UChicago Prof's Insider Trades Merit Prison, Feds Say
• Cos. Should Prepare For Gov't Grantee IP Reporting Update
• Circuit Split On Cannabis Prosecutions Heightens Uncertainty
• NY State Accuses CVS Of Illegal Service Tying
• Justices Must Correct Fed. Circ.'s Overreach On Patents
• Judge Orders Claim Estimation For J&J Talc Unit's Ch. 11
• Fla. Man Charged In $25M Medicare Fraud Scheme
• Senate Advances Bill To Create FDA-USPTO Patent Task Force
• 3M Unit Strikes Deal To Extend Earplug Suit Schedule
• Investors Want To Block $890M Go-Private Sale Of Radius
• Immigration Key To Fixing Semiconductor Scarcity, GAO Says
• FDA Must Enable More Testing To Contain Monkeypox Spread
• Illinois Medical Center Wants Out Of Merger Antitrust Suit
• Ohio Judge Blocks Air Force Vax Requirement Nationwide
• How Lawyers Can Set Ethical Boundaries Post-Pandemic
• Ex-CNA Insurance Atty Jumps To Hinshaw In Chicago
• Vet Slams 3M's Bid To Undo $50M Earplug Injury Verdict
• Biophysics IP Counsel Rejoins Buchanan Ingersoll
• Del. Jury Finds Kurin Infringed Rival's Blood-Testing Patent
• DC Circ. Affirms FDA's Denial Of Flavored Vape Applicants
• Ch. 11 Cheat Sheet: Aearo Technologies
• Pet Owners Say IDEXX Illegally Cornered Test Kit Market
• J&J Unit, Talc Claimants Spar Over Ch. 11 Case's Path
• TTAB Won't Let Radiology Co. Secure 'Your Body' Podcast TM
• Fed. Circ. Won't Rethink USPTO Cancer Patent App Ruling
• Full Fed. Circ. Urged To Reject Hirshfeld's Director Reviews
• 'Baffling' I'm Not Out Of Prison Yet, Ex-Insys Exec Says
• A Lawyer's Guide To Collecting Fees From Nonpaying Clients
• Teva Reaches $5B National Opioid Deal
• Female Atty Sues Former Firm For Sexual Discrimination
• FDA Inaction May Not Doom GSK Zofran MDL, 1st Circ. Hints
• Ex-BakerHostetler IP Partner Joins Blank Rome In DC
• These Law Firms Have The Most Diverse Equity Partnerships
• 3M Unit Seeks Ch. 11 Protection To Settle Earplug Claims
• 2nd Circ. Backs Pfizer Loss In Drug Copay Program Suit
• BioNTech, Pfizer Say They Didn't Infringe CureVac Patents
• PE Execs Want Out Of Suit Over Radiology Chain Stock Plan
• J&J Talc Unit, Tort Claimants Clash On Claim Estimation
• WTO Finds Turkey's Pharma Production Measures Unfair
• Amyris Investors' $13.5M Deal Over Inflated Royalties OK'd
• AstraZeneca Says Vidal Memo Backs Case Against Fintiv Rule
• How Lawyers Can Benefit From TikTok Without Being 'Cringe'
• Catching Up With Delaware's Chancery Court
• Patent Drafting Reminders In Fed. Circ. Skin Care Ruling
• Novartis Can't Shake Former Exec's Whistleblower Award
• CR Bard Wants Win Over Rest Of Pelvic Mesh Suit
• NM Patients Say Insurance Should Cover Cannabis
• How Reed Smith Notched A 'Sweeping' Opioid Trial Triumph
• 3 Firms Guide Dutch Biotech Startup's $326M SPAC Merger
• It's Maryland Versus Virginia In A Race To Adult-Use Cannabis
• Amazon, 3M Accuse Sellers Of Counterfeit Stethoscope Scam
• Countersuit Tossed In Hemp Harvesting Machine Dispute
• Ex-GOP Congressman, 8 Others Charged With Insider Trading
• Law360's Diversity Snapshot: What You Need To Know
• 5th Circ. Ends Pharma Group's Medicare Payback Suit
• Eli Lilly Pocketed $60M Meant For Medicaid, Ill. Jury Hears
• After Dobbs: Abortion Battles Hit The Courts, Soon The Polls
• Ex-Medical Device Co. CEO's Double Jeopardy Bid Falls Short
• Texas Court Revives Suit Over Erroneous DNA Test
• Inside A BigLaw-Boutique Alliance Tackling A Post-Roe World
• Ga. Opioid Trial Called Off After COVID-19 Outbreak
• Full Fed. Circ. Urged To Undo 'Extraordinary' Gilenya IP Ruling
• Faegre Drinker Loses Partner To Banner Witcoff
• Sandoz Loses Challenge To FDA Exclusivity For Sanofi Drug
• Ex-UChicago Prof Seeks No Jail Time For Insider Trading
• 7th Circ. Sides With VA On Tech's Disability Retaliation Claims
• Feds Want Role In 4th Circ. Rehearing Of Allergan FCA Case
• How The FTC Is Imposing Monetary Remedies Post-AMG
• 3rd Circ. Backs $1M FBAR Penalty Against Ex-Pharma CEO
• Drugmaker Says FDA Delayed OK Of Narcolepsy Medication
• CBD Extract Co. Says No Jurisdiction In 'Ponzi' Scheme Suit
• Health Hires: Ropes & Gray, BeiGene
• J&J, Ethicon Sink Failure-To-Warn Claim In Pelvic Mesh Trial
• In-House At A Cannabis Company: The Real Estate Issues
• Flint Jury Hears Atty Criticisms In Final Argument
• The Rulings That Quickly Made 2022 Huge For Health Law
• PTAB Judges Discuss Their Approach To New Fintiv Guidance
• SF, Walgreens Continue Opioid Bellwether Battle Post-Trial
• Chancery Approves Bioscience Co. Deal, Splits $850K Fees
• PTAB Mulls Validity Of Novartis Syringe IP In Regeneron Fight
• 3 Firms Guide Biopharma Co. ZyVersa's $109M SPAC Merger
• Crypto Dominos Keep Falling, J&J Wants Talc Injunction
• Must Your Client Pay An Opponent's Expert For Prep Time?
• Chancery Holding Amplifies Approach To Boardroom Issues
• House Passes Contraceptive Bill Post-Dobbs
• 3rd Circ. Finds Perrigo, AbbVie Settlement Bars Antitrust Suit
• Deals Rumor Mill: SoftBank, Porsche, ConocoPhillips
• Split 4th Circ. Clarifies CWA's Prosecution Requirements
• Flint Water Contractors Want 'A Pass,' Jury Hears In Closings
• Ex-Clinic COO's FCA Suit Trimmed, But Heads For Trial
• PTAB Axes Hypertension Drug IP Involved In Generic Fight
• NJ Announces Alliance With Feds To Protect Abortion Access
• Class Claimant Says Imerys Ch. 11 Stay Can't Pause J&J Suit
• Businesses Should Prepare For FTC Use Of Robinson-Patman
• The New Fintiv Guidance: Overcoming Discretionary Denials
• FDA Seeks Outside Help On Food And Tobacco Programs
• BigLaw IP Experts Head For Hoffmann & Baron In DC
• Inform Diagnostics Settles Mass. FCA Probe For $16M
• Impax Inks $145M Deal With Direct Purchasers In Opana MDL
• Jackson Walker Lands Health Care Partner In Houston
• 11th Circ. Lifts Block On Ga. Abortion Ban Law
• Biogen To Pay $900M To Settle Kickback Claims On Trial's Eve
• Feds Say Charges Filed In $1.2B Series Of Health Fraud Cases
• Greenberg Traurig Adds Trade Secrets Pro To Boston Office
• Oblon McClelland Scoops Partner From Dickinson Wright
• Last Flint Trial Witness Says Contractors Met Standards
• 'Sales Were King' For Drug Cos., Says Atty In Ga. Opioid Trial
• Top Product Liability Cases Of 2022: Midyear Review
• Goodwin Adds Partners In Tech M&A, Private Investment Funds
• J&J Wants Opioid Claims From NY Towns, Cities Tossed
• Product Liability Vs. Consumer Fraud: What's The Difference?
• The Biggest Trade Policy Stories Of 2022: Midyear Report
• AMA President Says Doctors Facing Uncertainty Post-Dobbs
• Bar Exam Policies On Menstruation Still Fall Short
• NY Worker's Family Gets $15M In Mesothelioma Verdict
• Coloplast Gets Win In Vaginal Mesh Device Suit
• Foley Hoag Starts Reproductive Health Unit In Wake Of Dobbs
• EU Accuses Illumina Of Jumping Gun On $8B Grail Deal
• FibroGen Can't Dodge Securities Suit Over Anemia Drug
• Drug Cos., Researchers Back Juno's 'Possession' Petition
• Justices Warned That Biogen's Loss Will End Drug Patents
• University Of Ky. Ducks Due Process Claims At 6th Circ.
• Sidley-Advised Diagnostics Co. Raises $225M In Funding
• Federal Circuit Upholds Invalidation Of Kidney Test Patents
• Georgia Says Dobbs Shows State Abortion Ban Is Valid
• Seagen Gets PGR Nixed Under Fintiv In Rehearing Decision
• 7th Circ. Affirms Tossing Of Case Against Ill. Hospital Chain
• Gilstrap Says AstraZeneca Rival Had No Undue Delay In IP Suit
• J&J Elevates Atty To General Counsel As Top Lawyer Retires
• Fee Bid In Bioscience Suit Deal Is Unfair, Chancery Told
• Keys To Crafting Hybrid Work Policies At Law Firms
• Haynes And Boone Adds Lathrop GPM IP Atty In DC
• 7 Firms Guide GSK Spin-Off Haleon In London Listing
• Trucker Wants RICO Claim Revived In Suit Against CBD Co.
• 1st Circ. OKs Pharmacist's 10-Year Term For Deadly Outbreak
• Catching Up With Delaware's Chancery Court
• Biden Scraps Plan To Nominate McConnell-Backed Judge Pick
• Can States Legally Ban FDA-Approved Abortion Pills?
• After Dobbs: The Latest Legal Battle Lines Over Abortion Care
• Impax Investor Attys Score $9.9M Fees In Price-Fixing Suit
• House Passes Bill To Suspend Imported Baby Formula Duties
• Novo Nordisk Hits Biocon With IP Suit Over Weight Loss Drug
• Your AI Program Probably Isn't A Person In A Court Of Law
• Justices Urged To End 'Ominous' Patent Trend In Biogen Case
• In-House At A Cannabis Company: The ESG Issues
• House Passes Bills To Protect Abortion Rights Post-Dobbs
• Patent Cases To Watch In The Second Half Of 2022
• J&J Unit Seeks To Halt Mississippi, New Mexico Talc Suits
• Illumina Pays Complete Genomics $325M To End DNA IP Row
• Bristol-Myers Opts To Drop Suit Rather Than Publish Award
• IP Forecast: 'Pulp Fiction' NFT Feud To Play In LA Court
• Texas Sues Feds Over Emergency Abortion Care Guidance
• How New USPTO Guidance Fine-Tunes Fintiv Application
• Pa. AG Pledges To Defend Abortion Access From Other States
• Ex-Novartis Sales Rep Claims Firing Was Retaliatory
• Republicans Block Bill To Protect Interstate Abortion Travel
• Tips For Handling Audio Data In E-Discovery Post-Pandemic
• Doctors Sue DHS, Medical Boards Over Freedom Of Speech
• Dems Push Biden For Health Emergency On Abortion
• Greenhouse Maker Says Cannabis Grower Infringed Patent
• Winston & Strawn Adds Ex-HHS Regulatory Atty In DC
• ECJ Urged To Rule Servier Agreements Are Anti-Competitive
• Rite Aid Quietly Inks Opioid MDL Deals, Litigation Freeze
• Walgreens Says SF Opioid Case Has 'Fatal Flaw' As Trial Ends
• Joint Juice Seeks Class Decertification After Trial Loss
• Crypto Issues Grow, Mediation Over Abuse OK'd In Ch. 11
• FDA Clears Novavax, Adding Option For COVID Vax Holdouts
• US Patent Takeaways From Russia Sanctions Exemption
• LegitScript To Face PharmacyChecker Suit Over Blacklisting
• Mass. Biotech Biz Gets PTAB To Wipe Alzheimer's Drug Patent
• Immunitas Therapeutics Hires Senda CLO As COO
• Ex-Exec Sues Over Ouster From Vape Product Co.
• GenapSys Cleared For Ch. 11 Loan With Sale Milestones
• Medical Biz Says SPAC Suit Belongs In Delaware, Not Texas
• Arnold & Porter Lands Life Sciences Partner From Reed Smith
• Justices Told Teva Skinny Label Loss 'Eviscerates' Certainty
• Walgreens Allowed Iffy Opioid Orders, SF Says At Trial Wrap
• Mylan Can't Stop AstraZeneca's Asthma Drug Patent Suit
• The Opposing View On Cannabis Legalization
• Ch. 11 Cheat Sheet: GenapSys
• Pfizer, Moderna Face New IP Litigation Over COVID Vaccines
• Catalyst Inks Deal To End Its 'Orphan Drug' Case
• Senate Committee Explores Post-Dobbs Abortion Landscape
• 7th Circ. Affirms Lupron Suit Dismissal As Too Late
• Arthrex Tells Full Fed. Circ. USPTO Can't Cherry-Pick Leader
• Ex-Theranos CEO Holmes' Sentencing Delayed Until October
• Ariz. Abortion Law Stopped For Now On Vagueness Ground
• Strategies For Effectively Marketing Law Firm ESG Practices
• Fee Fight Brewing Over Bioscience Co. Suit Deal In Chancery
• $58M Opioid Deal Cuts Allergan, Teva From SF Bellwether Trial
• GenapSys Opens Ch. 11 After Chancery Shakes Up Board
• Hospitals Must Provide Emergency Abortion Care, Feds Say
• Microsoft's New AI Medical Imaging Biz Defeats Patent Suit
• Zydus Faces Xtandi Cancer Drug Patent Suit
• NY AG Says Teva's Parent Belongs Back In Opioid Case
• Veterinarian Gets 11 Years In Horse Doping Crackdown
• Fla. Mother Claims Tainted Abbott Formula Made Baby Sick
• Justices Urged To Review On-Sale Bar Ruling In Catheter Case
• FDA Asked To Make Birth Control Pill Available OTC
• Venue Issues Drug Cos. Should Watch In Hatch-Waxman Suits
• Monsanto Beats Delaware's Suit Over PCB Contamination
• Catching Up With Delaware's Chancery Court
• Agreement Among Litigants Key To Using E-Discovery Tech
• Notes On Social Equity From A Former Cannabis Regulator
• USPTO Wants Fed. Circ. To Rethink Cancer Patent App Ruling
• 2 Firms Lead $320M Vertex Buy Of Diabetes Treatment Co.
• Cannabis Shops' Racial Bias Suit Over Licenses Tossed
• W.Va. Opioid Verdict Widens Judge-Jury Split On Vital Theory
• Texas Pol Threatens Sidley With Charges Over Abortion Policy
• 4 Takeaways From Ex-Theranos Exec Balwani's Fraud Verdict
• Lens.com Attys Sanctioned For 'Wild Goose Chase' In TM Row
• Chancery Prunes GenapSys Board, Orders Annual Meeting
• How Congress Is Addressing Employment Visa Backlog
• Law Groups Push 3rd Circ. To Toss J&J Bankruptcy Filing
• Judge Approves Deal To End Dr. Oz's 'Miracle' Diet Pills Suit
• Why J&J's Bankruptcy Is Still Alive And InfoWars' Is Not
• How The Pandemic Changed FDA Inspections
• NYS Courts Again Hit With Suit Over Vax Mandate
• UPDATED: Ex-Biotech Exec Drops Chancery Ouster Suit
• Biden Orders Agencies To Protect Abortion Access
• Hill-Rom Can't Beat Surgery Table Infringement Claim
• A Former Cannabis Regulator On Shaping A Nascent Industry
• Law School Admissions Shouldn't Hinge On Test Scores
• Flint Water Jury Hears Of Council Meeting Discord
• Invisalign Maker's 'Puffery' Isn't Investor Fraud, 9th Circ. Says
• Fla. Appeals Court Reverses $6M In Damages In Engle Case
• Ex-Medical Device Exec Charged With Insider Trading
• High Court Ruling Boosts Defenses In DOJ Health Care Cases
• GOP Cut Pharma's Taxes Offshore, Senate Report Finds
• Fed. Circ. Wary Of Undoing Endo Loss Over Vasostrict Fight
• 3 Firms Lead Meridian Bioscience's $1.53B Sale
• Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ.
• BakerHostetler Adds Ex-Winston & Strawn FDA Partner
• Banner Health Promotes Atty To Head Of Legal
• Clark Hill Must Face Claims From Ex-Client, Philly Judge Rules
• Former Theranos Exec Sunny Balwani Convicted Of Fraud
• Deals Rumor Mill: Merck, Sequoia, Ridgeback
• Chancery Won't Consider Firms' Bid To Lead Ionis Pay Suit
• Whistleblower Settles Fraud Case With DHS Contractor
• Justices Urged To Mend Circuit Split Over FCA Scienter
• $12.5M Class Deal Reached In Ionis-Akcea Drug Licensing Suit
• FTC Told Ban On Juul Sales Bolsters Altria Deal Challenge
• An Uncertain Future For HHS Drug Reimbursement Rates
• The Biggest Patent Rulings Of 2022: A Midyear Report
• FDA, USPTO Heads Look At Teaming Up On Drug Pricing
• Embracing Revenue Operations For Strong Law Firm Growth
• FDA Stays Juul Ban, Says More Review Needed
• USPTO Tells Fed. Circ. AIA Allows Gene-Editing Interference
• Biden Planned To Name Anti-Abortion Ky. Judge, Emails Show
• Premium Cigar Groups Get Win In Suit Over FDA Rulemaking
• J&J Talc Unit Headed For Pivotal Ch. 11 Hearing
• Drug Distributors Off Hook In W.Va. Opioid Trial
• Texas Justices Allow Enforcement Of Pre-Roe Abortion Ban
• Supreme Court Embraces Originalism In 'Momentous' Term
• Pro Say & The Term Discuss A Historic Supreme Court Term
• 9th Circ. Clears Calif. City Of Liability In Hazardous Water Suit
• Pa. County Sues Major Pharmacy Chains Over Opioid Controls
• NJ Takes On Dobbs With Passage Of Abortion Rights Laws
• The Firms That Won Big At The Supreme Court
• The Sharpest Dissents From The Supreme Court Term
• The Funniest Moments Of The Supreme Court Term
• Ky. Trial Judge Vacancy Tees Up Likely Biden-McConnell Deal
• FDA Flexes Muscle On Juul And Nicotine, But At What Cost?
• Catching Up With Delaware's Chancery Court
• Make Room For Serendipity In Your Legal Job Search
• Health Hires: Lewis Brisbois, Troutman Pepper
• Pot Co. Canopy Takes CBD Patent Row To Fed. Circ.
• The Fed. Circ. In June: A Few Decisions To Know
• Tepid Equity Markets Start 2nd Half Of '22 On Shaky Ground
• The Chattiest Justice Of The Term Is ...
• Breaking Down The Vote: The High Court Term In Review
• Jury Hands Endo Win In Opana Pay-For-Delay Case
• Ohio Supreme Court Declines To Block 6-Week Abortion Ban